New Mexico Angels

Nob Hill Therapeutics, Inc. is a biotechnology company focused on developing and marketing innovative dry powder nebulizers, specifically designed for the treatment of severe respiratory diseases. Founded in 2016 and based in Fayetteville, Arkansas, the company offers DryNeb, a groundbreaking nebulizer that operates differently from traditional aerosol mist devices. By utilizing a magnetically responsive element to create mechanical collisions in the dispersion chamber, DryNeb ensures consistent and reproducible delivery of medication, independent of the patient's inhalation force. This approach enhances the pulmonary route of drug delivery, which is gaining recognition for its ability to provide targeted, noninvasive administration of drugs directly to the lungs, resulting in improved bioavailability and faster therapeutic effects for patients suffering from various respiratory conditions. Nob Hill Therapeutics has secured exclusive licensing of this technology from the University of New Mexico, positioning itself to address substantial market opportunities in pulmonary drug delivery.

Nob Hill Therapeutics, Inc. is a biotechnology company focused on developing and marketing innovative dry powder nebulizers, specifically designed for the treatment of severe respiratory diseases. Founded in 2016 and based in Fayetteville, Arkansas, the company offers DryNeb, a groundbreaking nebulizer that operates differently from traditional aerosol mist devices. By utilizing a magnetically responsive element to create mechanical collisions in the dispersion chamber, DryNeb ensures consistent and reproducible delivery of medication, independent of the patient's inhalation force. This approach enhances the pulmonary route of drug delivery, which is gaining recognition for its ability to provide targeted, noninvasive administration of drugs directly to the lungs, resulting in improved bioavailability and faster therapeutic effects for patients suffering from various respiratory conditions. Nob Hill Therapeutics has secured exclusive licensing of this technology from the University of New Mexico, positioning itself to address substantial market opportunities in pulmonary drug delivery.